Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05150002
Other study ID # VasoStim
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 30, 2023
Est. completion date September 2027

Study information

Verified date July 2023
Source Insel Gruppe AG, University Hospital Bern
Contact Janine A Schlaeppi, MD
Phone +41 31 6320014
Email Janine.Schlaeppi@insel.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cerebral vasospasm is characterized by a vasoconstriction of cerebral arteries causing a reduction of cerebral blood flow (CBF) and leading to ischemia and infarction of the brain parenchyma. Cerebral vasospasm is a serious complication of aneurysmal subarachnoid hemorrhage (SAH) with high morbidity and overall mortality of 40-50%. Although the exact mechanisms of spinal cord stimulation (SCS) on the innervation of cerebral vessels are still unclear, several hypotheses have been formulated and studies in animals and human performed with very promising results. This is a proof of concept study to better understand the effect and mechanisms of cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH in human.


Description:

Cerebral vasospasm is characterized by a vasoconstriction of cerebral arteries causing a reduction of cerebral blood flow (CBF) and leading to ischemia and infarction of the brain parenchyma. Cerebral vasospasm is a serious complication of aneurysmal subarachnoid hemorrhage (SAH) with high morbidity and overall mortality of 40-50%. The exact pathophysiological mechanisms underlying cerebral vasospasm are still not known in detail. A wide range of different therapeutic options with various efficacies are available, triple-H therapy and endovascular treatment options like intra-arterial application of vasodilators e.g. Nimodipine or Papaverine or transluminal balloon angioplasty have been reported and are applied to prevent and treat cerebral vasospasm after SAH. Calcium channel blockers such as nimodipine or nicardipine improve outcome in patients after SAH and reduce the risk of secondary ischemia. The benefit of the different therapies is undoubted, but there is still potential for improvement concerning the rate of morbidity and mortality. Although the exact mechanisms of spinal cord stimulation (SCS) on the innervation of cerebral vessels are still unclear, several hypotheses have been formulated and studies in animals and human performed with very promising results. This is a proof of concept study to better understand the effect and mechanisms of cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH in human. Subjects are enrolled into the study, if radiographical vasospasms are detected in CTA, CTP, cerebral angiography or TCD. SCS leads are implanted within 12h after study enrolment following the investigator's standard practice. SCS will be continuously delivered until day 14 after SAH. Doppler ultrasound is performed before SCS lead implantation and repeated after implantation on a daily basis and appearance of a new neurological deficit device until 24h after stopping the stimulation. Efficacy of cervical SCS is further evaluated by CTA or angiography and CTA/P performed 48h and 96h after lead implantation, as well as on day 14 after SAH before stopping the stimulation. The SCS electrode(s) are explanted on day 15. Intracerebral pressure is monitored from day 7-15. Headache, measured as NRS 0-10 and the consumption of analgesics are monitored from day 7-15, at discharge, at 3 and 6 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date September 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Fisher 3 grade subarachnoid hemorrhage at presentation - Secured aneurysm by clipping or coiling - Is 18-75 years of age at the time of enrollment - Cerebral vasospasm: - Cerebral angiography o Narrowing of vessel lumen > 66% - Transcranial Doppler ultrasound - Mean flow velocity > 150 cm/s or - Lindegaard Index > 3 or - increase > 50 cm/s within 24 hours - Intracranial CT angiography o Narrowing of vessel lumen > 66% - Intracranial CT perfusion o Time To Drain (TTD) > 4.7 seconds - Is willing and capable of providing informed consent or existence of the presumed will of the patient by a relative or a legal representative - Written confirmation by a study independent physician to guarantee patient interest - Is willing and capable of complying with the study related requirements, procedures, and visits - No findings on spinal imaging preventing SCS lead implantation - Negative pregnancy test - No breast feeding Exclusion Criteria: - Untreated ruptured aneurysm - Cerebral infarction in the territory of the spastic arteries or massive disseminated infarction - Signs of cerebral herniation - Uncontrollable intracranial pressure - Infection - Coagulation disorder - Is participating in another interventional trial - Circulatory instability - Severe congestive heart failure - Patients with an elevated risk of bleeding - Known allergy to implanted materials (Silicon, Titanium)

Study Design


Intervention

Device:
Spinal cord stimulation
Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH

Locations

Country Name City State
Switzerland Dep. of Neurosurgery, Bern University Hospital Bern

Sponsors (1)

Lead Sponsor Collaborator
Insel Gruppe AG, University Hospital Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of baseline flow velocity The change of baseline flow velocity from the onset of vasospasm to day 14 assessed with Doppler ultrasound showing the effect of cervical SCS. 14 days after onset vasospasm
Secondary Vasospasm changes in angiography and perfusion in CTP Vasospasm changes in angiography and perfusion in CTP 48 hours after stimulation
Secondary Vasospasm changes in CTA and perfusion in CTP Vasospasm changes in CTA and perfusion in CTP 48 hours after stimulation
Secondary Vasospasm changes in angiography and perfusion in CTP Vasospasm changes in angiography and perfusion in CTP 96 hours after stimulation
Secondary Vasospasm changes in CTA and perfusion in CTP Vasospasm changes in CTA and perfusion in CTP 96 hours after stimulation
Secondary Vasospasm changes in CTA and perfusion in CTP Vasospasm changes in CTA and perfusion in CTP 14 days after stimulation
Secondary Vasospasm changes in angiography and perfusion in CTP Vasospasm changes in angiography and perfusion in CTP 14 days after stimulation
Secondary Triple-H therapy Development of symptomatic vasospasm from onset to day 14 with need for Triple-H therapy 14 days after stimulation
Secondary Angioplasty or intra-arterial application of vasodilators Development of symptomatic vasospasm from onset to day 14 with need for angioplasty or intra-arterial application of vasodilators 14 days after stimulation
Secondary Intracerebral pressure (ICP) Intracerebral pressure (ICP) Day 7- 14
Secondary Headache Headache measured by VAS Scale (Score 0-10 with 0 representing no pain, and 10 maximum pain intensity) Day 7- 14
Secondary Consumption of analgesics Consumption of analgesics Day 7- 14
Secondary Side effects of SCS Side effects of SCS Day 7- 14
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting NCT04189471 - Recovery After Cerebral Hemorrhage
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Completed NCT02872857 - Subarachnoid Hemorrhage Recovery And Galantamine Phase 1/Phase 2
Completed NCT03164434 - Influence of Drainage on EVD ICP-signal
Terminated NCT02216513 - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Phase 0
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT02389634 - Identification of Novel Molecular Markers for Vasospasm
Completed NCT01077206 - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage Phase 2/Phase 3
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Recruiting NCT05113381 - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH N/A
Completed NCT04052646 - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT06033378 - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage. N/A
Completed NCT04308577 - Diet Induced Ketosis for Brain Injury - A Feasibility Study N/A